Assignee
ACCUTAR BIOTECHNOLOGY INC
US·17 granted patents·15 pending applications·49 citations·filing 2017–2025
Top patents by PatentIndex Score
32 records- 0197US11420956B2Ureas having Androgen Receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Aug 23, 2022·6 cites·21 claims
- 0297US10800770B1Chroman derivatives having estrogen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Oct 13, 2020·9 cites·22 claims
- 0396US11312702B2Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Apr 26, 2022·4 cites·20 claims
- 0495US11535606B2Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Dec 27, 2022·4 cites·34 claims
- 0595US11261178B2Chroman derivatives having estrogen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Mar 1, 2022·5 cites·9 claims
- 0695US10836749B1Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Nov 17, 2020·3 cites·25 claims
- 0793US11220490B2Ureas having androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2021·Granted Jan 11, 2022·2 cites·10 claims
- 0885US9944632B2Compounds having estrogen receptor alpha degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2017·Granted Apr 17, 2018·3 cites·12 claims
- 0983US10923214B2Neural network for predicting drug propertyACCUTAR BIOTECHNOLOGY INC·Filed 2018·Granted Feb 16, 2021·8 cites·20 claims
- 1080US10696659B2Compounds having estrogen receptor alpha degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2019·Granted Jun 30, 2020·2 cites·30 claims
- 1175US2023135173A1Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1274US2023150973A1Novel ureas having androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 1373US11521712B2Computational method for classifying and predicting ligand docking conformationsACCUTAR BIOTECHNOLOGY INC·Filed 2018·Granted Dec 6, 2022·3 cites·24 claims
- 1470US10968212B2Compounds having estrogen receptor alpha degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2019·Granted Apr 6, 2021·0 cites·48 claims
- 1569US12338248B2Aminopyrimidine derivatives as cyclin-dependent kinase inhibitorsACCUTAR BIOTECHNOLOGY INC·Filed 2024·Granted Jun 24, 2025·0 cites·48 claims
- 1668US10450307B2Compounds having estrogen receptor alpha degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2018·Granted Oct 22, 2019·0 cites·17 claims
- 1767US2024317777A1Novel macrocyclic aminopyrazole compounds as cdk2 inhibitorsACCUTAR BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 1865US11117885B2Compounds having estrogen receptor alpha degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Sep 14, 2021·0 cites·18 claims
- 1965US2024208909A1Substituted quinoline derivatives having sos1 inhibition activities and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2065US2024190842A1Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2165US2025002473A1Quinoxaline derived sulfonamides with egfr degradation activities and their uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2024·Application pending·0 cites
- 2264US2025352548A1BTK Reducing Molecules for Treatment of Cancers and Immune System DisordersACCUTAR BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2361US11530222B2Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degradersACCUTAR BIOTECHNOLOGY INC·Filed 2022·Granted Dec 20, 2022·0 cites·30 claims
- 2461US2024059698A1Heteroaryl compounds as egfr inhibitors and their usesACCUTAR BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2560US2024132464A1Heterocyclic compounds as e3 ligase inhibitorsACCUTAR BIOTECHNOLOGY INC·Filed 2023·Application pending·0 cites
- 2659US2024398805A1Quinazoline derived compounds as egfr inhibitors and their uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2759US2024051940A1Sulfonamides with egfr inhibition activities and their use thereofACCUTAR BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 2857US2022112204A1Substituted dihydropyranopyrimidine compounds as kras inhibitorsACCUTAR BIOTECHNOLOGY INC·Filed 2021·Application pending·0 cites
- 2956US2025381179A1Chroman-based compounds for treating cancerACCUTAR BIOTECHNOLOGY INC·Filed 2025·Application pending·0 cites
- 3055US12331061B2Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereofACCUTAR BIOTECHNOLOGY INC·Filed 2020·Granted Jun 17, 2025·0 cites·36 claims
- 3151US2022238191A1Molecular modeling with machine-learned universal potential functionsACCUTAR BIOTECHNOLOGY INC·Filed 2022·Application pending·0 cites
- 3241US2017329892A1Computational method for classifying and predicting protein side chain conformationsACCUTAR BIOTECHNOLOGY INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ACCUTAR BIOTECHNOLOGY INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →